Kappa agonist compounds and pharmaceutical formulations thereof
申请人:——
公开号:US20030144272A1
公开(公告)日:2003-07-31
Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided.
The compounds of formulae I, II, IIA, III, IIIA, IIIB, IIIB-i, IV and IVA have the structure:
1
2
wherein
R
1
, R
2
, R
3
, R
4
; and
X, X
4
, X
5
, X
7
, X
9
;
Y, Z and n are as described in the specification.
2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.
[EN] HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES AYANT UNE ACTIVITÉ DE MODULATION DE ROR(GAMMA)T
申请人:TAKEDA PHARMACEUTICALS CO
公开号:WO2018030550A1
公开(公告)日:2018-02-15
The present invention relates to a compound that may have an ROR(gamma)t modulating activity and can thus be useful in the treatment of cancer.
本发明涉及一种可能具有ROR(gamma)t调节活性的化合物,因此可用于癌症治疗。
An environmentally benign and selective electrochemical oxidation of sulfides and thiols in a continuous-flow microreactor
作者:Gabriele Laudadio、Natan J. W. Straathof、Menno D. Lanting、Benny Knoops、Volker Hessel、Timothy Noël
DOI:10.1039/c7gc01973d
日期:——
A practical and environmentally benign electrochemical oxidation of thioethers and thiols in a commercially-available continuous-flow microreactor is presented. Water is used as the source of oxygen to enable the oxidation process. The oxidation reaction utilizes the same reagents in all scenarios and the selectivity is solely governed by the applied potential. The procedure exhibits a broad scope
[EN] NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5<br/>[FR] NOUVEAUX DERIVES DE PIPERIDINE/8-AZABICYCLO [3.2.1] OCTANE UTILISES COMME MODULATEURS DES RECEPTEURS CCR5 DE LA CHEMOKINE
申请人:ASTRAZENECA AB
公开号:WO2006001752A1
公开(公告)日:2006-01-05
Compounds of formula (I) wherein neither R4 nor R5 is hydrogen; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).